2023 World Conference on Lung Cancer (Posters)-EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC

EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the LITE-Risk prognostic model in patients with metastatic non-small cell lung cancer (NSCLC) who were treated with consolidation durvalumab or first-line osimertinib. The LITE-Risk model generates a risk stratification based on three baseline characteristics: lactate dehydrogenase (LDH), derived neutrophil-to-lymphocyte ratio (dNLR), and performance status (ECOG). The study aimed to determine whether the LITE-Risk model, previously developed and validated in advanced NSCLC patients treated with immune checkpoint inhibitors (ICI), could also predict outcomes in these additional patient cohorts.<br /><br />The study analyzed data from the Glans-Look Lung Cancer Research Database, a registry of patients treated in routine practice. The analysis included 66 durvalumab-treated patients and 65 osimertinib-treated patients. The two cohorts differed significantly in baseline characteristics related to disease stage and the biological underpinnings of EGFR-mutation positive disease. Osimertinib-treated patients had a higher rate of LDH above the upper limit of normal and ECOG 2, resulting in a higher proportion of patients in the Poor category of the LITE-Risk score.<br /><br />Interestingly, the LITE-Risk score failed to show prognostic ability among durvalumab-treated patients but was able to differentiate survival outcomes among osimertinib-treated patients. A Poor LITE-Risk score was associated with significantly reduced progression-free survival (PFS) and overall survival (OS) in this cohort. The LITE-Risk score also showed good predictive ability in this population.<br /><br />The authors concluded that the LITE-Risk score has additional utility in discriminating outcomes in osimertinib-treated EGFR-mutation positive patients. However, they emphasized the need for formal validation of the LITE-Risk model in this setting and among other systemically-treated advanced NSCLC cohorts. They also highlighted the potential benefits of a user-friendly and readily accessible treatment-agnostic prognostic score in clinical practice for advanced NSCLC patients.

Asset Subtitle

Amanda Gibson

Meta Tag

Speaker Amanda Gibson

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

LITE-Risk prognostic model

metastatic non-small cell lung cancer

consolidation durvalumab

first-line osimertinib

lactate dehydrogenase

derived neutrophil-to-lymphocyte ratio

performance status

Glans-Look Lung Cancer Research Database

immune checkpoint inhibitors

EGFR-mutation positive disease